Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Solifenacin | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Solifenacin | hsa00190 | Oxidative phosphorylation | 5.12E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Solifenacin | hsa00500 | Starch and sucrose metabolism | 1.34E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Solifenacin | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Solifenacin | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Solifenacin | hsa00730 | Thiamine metabolism | 3.83E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Solifenacin | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Solifenacin | hsa00830 | Retinol metabolism | 2.20E-02 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Solifenacin | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | Solifenacin | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Solifenacin | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Solifenacin | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Solifenacin | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Solifenacin | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Solifenacin | hsa04064 | NF-kappa B signaling pathway | 9.70E-03 | 12 | O00463, P14778, P01584, P01375, Q04759, Q13077, Q16548, P06239, Q8WV28, P24522, P09341, Q9NQC7 | TRAF5, IL1R1, IL1B, TNF, PRKCQ, TRAF1, BCL2A1, LCK, BLNK, GADD45A, CXCL1, CYLD | More | | Solifenacin | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Solifenacin | hsa04217 | Necroptosis | 2.24E-04 | 12 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | | Solifenacin | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | Solifenacin | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Solifenacin | hsa04613 | Neutrophil extracellular trap formation | 8.84E-04 | 19 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, P0C0S5, Q93077, P62807, O60814, P68431, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, H2AFZ, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Solifenacin | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Solifenacin | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Solifenacin | hsa04625 | C-type lectin receptor signaling pathway | 8.11E-03 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Solifenacin | hsa04640 | Hematopoietic cell lineage | 4.31E-02 | 10 | P13612, P14778, P27930, P15144, P11836, P09693, P01732, P13765, P01375, P01584 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD3G, CD8A, HLA-DOB, TNF, IL1B | More | | Solifenacin | hsa04650 | Natural killer cell mediated cytotoxicity | 4.33E-03 | 10 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Solifenacin | hsa04657 | IL-17 signaling pathway | 1.56E-02 | 8 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | Solifenacin | hsa04658 | Th1 and Th2 cell differentiation | 4.59E-04 | 10 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765, P23458 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB, JAK1 | More | | Solifenacin | hsa04659 | Th17 cell differentiation | 4.34E-04 | 11 | Q04759, Q16539, P06239, P13765, P14778, Q9UL17, P23771, P01584, P09693, P20963, P23458 | PRKCQ, MAPK14, LCK, HLA-DOB, IL1R1, TBX21, GATA3, IL1B, CD3G, CD247, JAK1 | More | | Solifenacin | hsa04660 | T cell receptor signaling pathway | 1.11E-02 | 11 | P01375, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Solifenacin | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Solifenacin | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Solifenacin | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Solifenacin | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Solifenacin | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Solifenacin | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.17E-02 | 8 | P14778, P01584, P51828, P22694, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, MAPK14, ITPR1, PRKCQ, CALM2 | More | | Solifenacin | hsa04912 | GnRH signaling pathway | 4.33E-02 | 6 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB | More | | Solifenacin | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Solifenacin | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Solifenacin | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Solifenacin | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Solifenacin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Solifenacin | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Solifenacin | hsa05140 | Leishmaniasis | 1.29E-03 | 13 | P13612, O75015, P14598, P23458, P42224, P13765, O60603, P25963, P01375, P01584, P29350, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, JAK1, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, IL1B, PTPN6, MAPK14, NCF4 | More | | Solifenacin | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Solifenacin | hsa05144 | Malaria | 1.13E-03 | 6 | P60033, O60603, P01375, P35443, P01584, P26718 | CD81, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Solifenacin | hsa05146 | Amoebiasis | 4.25E-02 | 9 | P01584, P09341, P14778, P27930, P01375, O60603, P05089, P22694, P08311 | IL1B, CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | | Solifenacin | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Solifenacin | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | | Solifenacin | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | | Solifenacin | hsa05202 | Transcriptional misregulation in cancer | 6.59E-03 | 15 | P17844, P14780, P27930, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | DDX5, MMP9, IL1R2, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Solifenacin | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Solifenacin | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Solifenacin | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Solifenacin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 5.23E-03 | 8 | O95267, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539 | RASGRP1, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14 | More | | Solifenacin | hsa05321 | Inflammatory bowel disease | 1.21E-02 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | Solifenacin | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Solifenacin | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Solifenacin | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Solifenacin | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | |